Olin Corporation announced it will release its third quarter 2026 financial results on October 29, followed by a management review and Q&A session on October 30. The event will include a live webcast accessible via the company website and a telephonic replay available for seven days. This update is important for investors to assess Olin's performance in its chemical and ammunition manufacturing businesses. The webcast will remain available for replay for one year after the event.
Olin Corporation's upcoming third quarter 2026 earnings call is noted here alongside Pluang's Basic Materials sector market data. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 06, 2026 03:02 WIB: out of 38 priced US stocks, 20 rose and 18 fell. Notable movers include FCX at USD 71.99 with a 1-day change of +3.88% and a Pluang order activity of 58% Sell / 42% Buy, JCI at USD 156.24 with +2.95% change and 35% Sell / 65% Buy order activity, and VALE at USD 13.75 with +2.23% change and 36% Sell / 64% Buy order activity.
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
